Company Insights

VBIV customer relationships

Explore interactive graphBrowse insights index
VBIV customer relationship map

VBI Vaccines (VBIV): Commercial Partnerships and Customer Footprint — what investors should know

VBI Vaccines monetizes an asset-light commercial model primarily through licensing, manufacturing and product sales of its vaccine candidates (notably PreHevbrio/PreHevbri), turning IP and clinical-stage assets into near-term revenue via partner deals and retail product placements. The company leverages regional licensing agreements and supply relationships to scale distribution without fully funding global commercialization, capturing royalties, license fees, and product sales margins. For a concise map of these customer and partner ties, visit https://nullexposure.com/.

Business model drivers are clear: partner monetization of clinical-stage assets, selective supply commitments, and retail channel distribution. These drivers put emphasis on deal-making capacity and partner execution rather than capital-intensive in-house sales forces.

Key takeaways up front:

  • Revenue is sourced both from direct U.S. product sales and from licensing/partner revenues in other regions.
  • Large retail distribution (including national chains) supports reorder-driven product sales.
  • Licensing and IP transfers have been used to de-risk development and generate near-term cash consideration.

How those elements combine, and the counterparty roster behind them, are detailed below.

How VBI structures customer relationships in practice

VBI operates with a contracting posture oriented toward exclusive regional licenses and manufacturing/IP transfers, supplemented by direct product sales into U.S. retail and pharmacy channels. This reduces up-front commercial overhead while concentrating execution risk into partner performance and supply chain delivery. The mix produces a revenue profile split between product sales (U.S.) and license/service income (partners and collaborators).

Operational characteristics investors should track:

  • Concentration: Partner-driven revenue is concentrated around a handful of licensing deals and large retail buyers, so a small number of counterparties drive outsized near-term cash flows.
  • Criticality: Partners often handle regional commercialization, making partner execution critical to VBI’s top-line realization.
  • Maturity: Relationships span from recent FY2026 licensing arrangements to earlier FY2024 IP/manufacturing deals, indicating a multi-year, staged monetization strategy.

If you want a deeper roster review or modelling support, review our partner coverage at https://nullexposure.com/.

Customer and partner relationships — the full list, explained

Below are every relationship surfaced in the public record for VBI’s customer/partner scope, each summarized and sourced.

Brii Biosciences (Brii Bio) — exclusive APAC license for PreHevbri (FY2026)

VBI executed an exclusive license with Brii Biosciences for development and commercialization of PreHevbri across the Asia Pacific region (excluding Japan), handing regional rights to Brii while preserving other territorial channels for VBI or other partners. According to VBI’s FY2026 company release, this is a strategic regional licensing arrangement aimed at accelerating market access in APAC. Source: VBI press release, FY2026 (vbivaccines.com press release).

Brii Biosciences — IP and manufacturing deal for VBI-2601 (FY2024)

Earlier activity with Brii included an IP and manufacturing transfer of VBI-2601 to Brii under a deal reportedly structured to deliver up to $33 million in consideration, a move that converted an in‑house asset into partner-funded development and supply. FiercePharma reported this FY2024 transaction as a discrete IP/manufacturing agreement that transferred operational responsibility and generated near-term proceeds. Source: FiercePharma, FY2024.

Valneva — partner purchasing PreHevbri for Europe (FY2026)

VBI recognizes revenue tied to sales of PreHevbrio in the U.S. and sales of PreHevbri to partner Valneva in Europe, with license and R&D services revenue linked to the Brii agreements also contributing to the uplift in reported revenue for FY2026. The FY2026 company financial commentary explicitly cites product sales to Valneva as a revenue driver in Europe. Source: VBI press release, FY2026 (vbivaccines.com press release).

Walmart — national retail ordering supports U.S. product sales (FY2026)

VBI’s U.S. retail channel execution is underpinned by strong ordering from national chains including Walmart, which the company cites as a contributor to retail usage and product sales volume in FY2026. This relationship underlines the significance of large pharmacy/retail chains to VBI’s U.S. revenue stream. Source: VBI press release, FY2026 (vbivaccines.com press release).

COVAX Facility / CEPI collaboration — allocation pathway for CEPI-supported vaccines (FY2021)

VBI’s collaboration with CEPI included an agreement that CEPI‑supported vaccine candidates would be made available to the COVAX Facility for procurement and allocation if proven safe and effective, embedding VBI’s assets into global pandemic response distribution channels. This FY2021 arrangement places VBI’s candidates in a procurement pathway aimed at equitable supply for global markets. Source: CEPI announcement, FY2021 (cepi.net).

What the relationship map implies for investors

Collectively, these engagements show a hybrid commercialization model: VBI retains direct U.S. commercialization while outsourcing regional commercialization and manufacturing through licensing and IP transfers. That structure produces a few predictable implications for investors:

  • Revenue concentration risk is real. A limited number of partners and large retail buyers account for meaningful near-term revenue, increasing sensitivity to partner execution or purchasing cycles.
  • Capital efficiency through partner monetization is core. Licensing deals convert development-stage assets into non-dilutive or cash-producing arrangements, shortening time-to-cash and transferring commercialization risk.
  • Execution risk shifts off VBI’s balance sheet but remains operationally critical. Partner manufacturing, regulatory progress, and retail reorder behavior determine whether licensed opportunities convert to sustained revenue.

Risk and upside considerations to watch

  • Upside: Successful regional launches by Brii and Valneva could amplify license and royalty streams while sustained national retail orders would stabilize U.S. product revenue.
  • Risk: Slippage in partner timelines, manufacturing handoffs, or retailer demand will compress near-term cash flow given the concentrated partner base.
  • Regulatory and global allocation mechanisms (e.g., COVAX) introduce additional policy-related timing and pricing variables.

For tailored intelligence on counterparty concentration and to stress-test partner scenarios in financial forecasts, visit https://nullexposure.com/.

Final perspective and next steps for investors

VBI’s commercial posture is deliberately partnership-centric: licenses and IP transfers provide capital and reach; retail partnerships provide immediate sales volume. That combination offers a clear path to revenue with attendant concentration and execution risks that investors should quantify in valuation models.

If you are modeling VBIV or monitoring counterparty delivery, anchor scenarios on partner launch timelines and retailer reorder patterns, and track announcements from Brii, Valneva, and national retail chains closely. For more detailed partner-level analysis and continuous monitoring, see our research hub at https://nullexposure.com/.